A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients
ConclusionsNeoadjuvant cetuximab/TPF followed by chemoradiotherapy in locoregional oesophageal carcinoma patients is feasible and offers a modest response rate in this trial. The results of combining trimodality neoadjuvant treatment with cetuximab are consistent with the literature.Registration: The study is registered atClinicalTrials.gov (NCT00733889).
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Erbitux | Esophagus Cancer | Gastroenterology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Oesophagus | Skin Cancer | Squamous Cell Carcinoma | Study | Taxotere | Toxicology